MedTrace Logo

A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule

NCT04313205 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-07-15

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics of JKB-122 tablets with JKB-122 capsules in healthy male subjects subjects.

Conditions

  • Autoimmune Hepatitis

Interventions

DRUG

JKB-122 in capsule or tablet form

JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form

Sponsors & Collaborators

  • TaiwanJ Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-31
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04313205 on ClinicalTrials.gov